Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Multi-Agent Therapy May Overcome CAR T Resistance in B-Cell Malignancies
Treatment with chimeric antigen receptor T-cells has induced unprecedented overall response rates and complete response rates in patients with relapsed/refractory B cell malignancies.
Optimizing care with CAR T-cell therapy now and in the future for patients with ...
Get an update on chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies, including guidance on referral and toxicity management, in these interviews with five experts.
Off-the-Shelf NK Immunotherapy With Chemotherapy and Transplant Shows Early Acti...
Cord blood–derived natural killer (NK) immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant (ASCT), showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma (NHL), according to data from a phase 2 trial (NCT03019640) presented in a poster during the 2021 Transplant & Cellular Therapy Meetings.
Trispecific antibody targets cancer cells, natural killer cells
Several treatments for cancer have been devised by science, but unfortunately none of them are completely efficient or foolproof. Novel treatments with minimum side effects are one of the main aims of the ongoing cancer research.
Can BiTE Molecules Make Off-the-Shelf Immuno-Oncology a Reality?
In hematologic malignancies, a new class of molecules is emerging that may ultimately offer clinical benefits comparable to those chimeric antigen receptor T-cell therapies while reducing some of the negatives associated with them.
Key Takeaways from the First-in-Human Study of Odronextamab in B-cell NHL
Rajat Bannerji, MD, PhD, discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma.
Browse this week's featured selection of scientific publications
A new selection of scientific publications relating to the latest developments in immunotherapy are added to our website weekly. Here are this week's must-read highlights.
ZUMA-5: high ORR and CR for R/R iNHL with axi-cel
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, gives an update on the ongoing Phase II ZUMA-5 trial (NCT03105336) of axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR)-T cell therapy, for patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL), including follicular lymphoma and marginal zone lymphoma (MZL).
iwCAR-T meeting 2020: featured sessions
During iwCAR-T 2020, some of the world’s leading clinical researchers shared their perspectives on how to place our evolving understanding in a clinical context and thereby optimize clinical care.
Bispecific anti-CD20 and anti-CD19 CAR T Cell Therapy Shows Efficacy in B Cell M...
Nirav N. Shah, MD, an associate professor at the Medical College of Wisconsin, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor (CAR) T cells in a phase 1 dose escalation and expansion trial (NCT03019055) for relapsed B cell malignancies.